Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$7.17
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 7, 2026 | $-0.08 | $-0.12 | Miss -50.0% | $-0.12 | $26.5M | $29.1M | +9.8% | 1D Pre+2.7% | On-Day+4.2% | 1D Post+0.7% |
Q ended Mar 31, 2026 Reported May 7, 2026 | $-0.07 | $-0.10 | Miss -42.9% | — | $31.6M | $22.5M | -28.8% | 1D Pre+3.3% | On-Day-12.1% | 1D Post+5.7% |
Q ended Dec 31, 2025 Reported Mar 12, 2026 | $0.04 | $0.04 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Met 0.0% |
| — |
| $35.4M |
| $37.2M |
| +5.1% |
| 1D Pre+2.6% |
| On-Day-6.3% |
| 1D Post-3.2% |
Q ended Sep 30, 2025 Reported Nov 7, 2025 | $-0.02 | $0.03 | Beat +250.0% | — | $32.9M | $30.6M | -7.0% | 1D Pre-0.7% | On-Day-1.8% | 1D Post+9.8% |